Laboratory monitoring of pentasaccharide in a dog model of hemodialysis

Thrombosis Research

Volumn 96, Issue 2, 1999, Pages 115-124

  Hoppensteadt, Debra A ^a   Jeske, Walter P ^a   Walenga, Jeanine M ^a   Fu, Kaiding ^a   Yang, Liu Hui ^a   Ing, Todd S ^b   Herbert, Jean Marc ^c   Fareed, Jawed ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b Department of Renal Services ^*  (United States)

^c SANOFI   (France)

Author keywords

Hemodialysis; Heparin; Laboratory monitoring; Pentasaccharide

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; FONDAPARINUX; HEPARIN; PENTASACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG TARGETING; HEMODIALYSIS; INTRAVENOUS DRUG ADMINISTRATION; LABORATORY; MONITORING; NONHUMAN; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOGENESIS; THROMBOSIS;

ANIMALS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FIBRINOLYTIC AGENTS; LABORATORY TECHNIQUES AND PROCEDURES; MODELS, BIOLOGICAL; MONITORING, PHYSIOLOGIC; OLIGOSACCHARIDES; RENAL DIALYSIS;

EID: 0032711809     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(99)00094-8     Document Type: Article

References (18)

1. Samama M.M., Walenga J.M., Kaiser B., Fareed J. Specific factor Xa inhibitors. Verstate M., Topol E.J. Cardiovascular Thrombosis-Thrombocardiology. 1998;173-188 Lippincott Raven Press, Philadelphia.
2. Walenga J., Fareed J., Petitou M., Samama M., Lormeau J.C., Choay J. Intravenous antithrombotic activity of a synthetic heparin pentasaccharide in a human serum induced stasis thrombosis model. Thromb Res. 43:1986;243-248.
3. Herbert J.M., Herault J.P., Bernat A., Van Amsterdam R.G.M., Lormeau J.C., Petitou M., Van Boeckel C., Hoffman P., Meuleman D.G. Biochemical and pharmacologic properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood. 91(11):1998;4197-4205.
4. Fareed J., Hoppensteadt D.A., Walenga J.M., Bick R. Current trends in the development of anticoagulant and antithrombotic drugs. Med Clin North Am. 78:1994;713-731.
5. Boneu B., Necciari J., Cariou R., Gabaig A.M., Kieffer B., Dickinson J., Lamond G., Moelker H., Mant T. Pharmacokinetics and tolerance of the natural pentasaccharide (SR 90107/Org 31540) with high affinity to antithrombin III in man. Thromb Haemost. 74:1994;1754-1759.
6. Herbert J.M., Herault J.P., Bernat A., Van Amsterdam R.G., Vogel G.M., Lormeau J.C., Petitou M., Meuleman D.G. Biochemical and pharmacologic properties of SANORG 32701. Comparison with the "synthetic pentasaccharide" (SR 90107/ORG 31540) and standard heparin. Circulation Res. 79:1996;590-600.
7. Cadroy Y., Hanson S.R., Harker L.A. Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates. Thromb Haemost. 70:1993;631-635.
8. Walenga JM. Factor Xa inhibition in mediating antithrombotic actions: Application of a synthetic pentasaccharide. Ph.D. Thesis, University of Paris VI, 1987;247-278.
9. Hoppensteadt D.A., Jeske W.P., Walenga J.M., Fu K., Yang L.H., Ing T., Herbert J.M., Fareed J. Efficacy of pentasaccharide in a dog model of hemodialysis. Thromb Res. 88:1997;159-170.
10. Jun L., Arnout J., Vanhove P., Dol F., Lormeau J.C., Herbert J.M., Collen D., Van de Werf F. Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs. Coronary Artery Disease. 6(3):1995;257-263.
11. Van Wyk V., Badenhorst P.N., Luus H.G., Kotze H.F. A comparison between the use of recombinant hirudin and heparin during hemodialysis. Kidney International. 48:1995;1338-1343.
12. Vanholder R.C., Camez A.A., Veys N.M., Soria J., Mirshahi M., Soria C., Ringoir S. Recombinant hirudin; a specific thrombin inhibiting anticoagulant for hemodialysis. Kidney International. 45:1994;1754-1759.
13. Grau E., Siguenza F., Maduell F., Linares M., Olaso M.A., Martinez R., Caridad A. Low molecular weight heparin (CY 216) versus unfractionated heparin in chronic hemodialysis. Nephron. 62:1992;13-17.
14. Mahul P., Raynaud J., Favre J.P., Jospe R., Decousus H., Auboyer C. Heparin-induced thrombocytopenia during hemodialysis in intensive care; use of a low molecular weight heparinoid, ORG 10172 (Orgaran). Annales Francaises d'Anesthesia et de Reanimation. 14:1995;29-32.
15. Kerr P.G., Mattingly S., Lo A., Atkins R.C. The adequacy of fragmin as a single bolus dose with reused dialyzers. Artificial Organs. 18:1994;416-419.
16. Walenga J.M., Koza M., Lewis B.E., Pifarré R. Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new anticoagulant agents. Clin Appl Thromb Haemost. 2(Suppl 1):1996;S21-S27.
17. Warkentin T.E., Levine M.N., Hirsh J., Horsewood P., Roberts R.S., Gent M., Kelton J.G. Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med. 332:1995;1330-1335.
18. Pifarré R., Walenga J.M., Fareed J. Clinical disadvantages with the use of heparin as an anticoagulant. Pifarré R. New Anticoagulants for the Cardiovascular Patient. 1997;1-9 Hanley & Belfus, Inc, Philadelphia.